Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Anlotinib, and Chemotherapy for Resectable NSCLC
NCT06977828Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06977828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977828.